| Application no. and date | 03809644.2 (espacenet) (Federated) (European Patent Register), 20031024 | | Patent/reg. no. and date | DK/EP 1578439, 20110727 | | Publication date | 20050928 | | Priority no. and date | US 421262 P, 20021024 | | EP pub. no. and date |
EP 1578439 20050928 | | Effective date | | | Applicant/owner | AbbVie Biotechnology Ltd, Harbour Fiduciary Services Limited
Thistle House
4 Burnaby Street
Hamilton Pembroke HM 11 , BM | | Applicant ref. no. | P006969EPDK1 | | Inventor | KAYMAKCALAN, Zehra, 4 Piccadilly Way
Westborough, MA 01581, US,
KAMEN, Robert, 60 Woodmere Drive
Sudbury, MA 01776, US | | Representative | CHAS. HUDE A/S, Langebrogade 3B, 1411 København K, DK | | Opponent | | | IPC Class | A61K 38/19 (2006.01) , A61K 39/395 (2006.01) , C07K 14/715 (2006.01) , C07K 16/24 (2006.01) | | Title | Lavdosisfremgangsmåde til at behandle forstyrrelser, i hvilke TNF-alfa-aktiviteten er skadelig | | Int. application no. | US2003033973 | | Int. publication no. | WO2004037205 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
